Cold storage of organotypically cultured skin equivalents for clinical applications

a technology for clinical applications, applied in the field of cold storage of organotypically cultured skin equivalents for clinical applications, can solve the problems of inability to effectively and efficiently preserve engineered tissues, inability to meet the needs of clinical use, so as to improve the availability and clinical utility of these products.

Inactive Publication Date: 2009-06-11
STRATATECH
View PDF10 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]Accordingly, what is needed in the art are improved methods of preparing engineered tissues and cells for storage under conditions that are routinely available at the point of use. As all clinical facilit

Problems solved by technology

Although a multitude of revolutionary and economically important applications for engineered tissues and organs exist in the human health arena, the full economic potential of the industry is far from realized.
A major impediment to the acceptance of engineered tissues by medical practitioners, healthcare providers, and second party payers is the lack of a means to effectively and efficiently preserve engineered tissues.
The nature of living cells and tissue products makes them impractical for long-term storage.
These inventory losses, on top of already costly manufacturing process, have forced prices to impractical levels.
Such

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cold storage of organotypically cultured skin equivalents for clinical applications
  • Cold storage of organotypically cultured skin equivalents for clinical applications
  • Cold storage of organotypically cultured skin equivalents for clinical applications

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0060]This example describes a method for the production of skin equivalents.

[0061]Media. The organotypic culture process uses six different culture media: 3T3 feeder cell medium (TM); human fibroblast growth medium (FGM); NIKS® medium (NM); plating medium (PM); stratification medium A (SMA); and stratification medium B (SMB). TM is used to propagate 3T3 cells that act as feeder cells for NIKS® cells in monolayer culture. TM is a mixture of Dulbecco's modified Eagle's medium (DME, GibcoBRL) supplemented with 10% calf serum (Hyclone). FGM is a commercially available fibroblast growth medium (Clonetics) that is used to propagate the normal human dermal fibroblast cells (NHDFs) for use in STRATAGRAFT® skin equivalent and STATATEST skin equivalent dermal equivalent layers. NM is used to grow NIKS® keratinocytes. NM is a 3:1 mixture of Ham's F-12 medium (GibcoBRL) and DME supplemented with 2.5% fetal clone II (Hyclone), 0.4 μg / ml hydrocortisone (Calbiochem), 8.4 ng / ml cholera toxin (ICN)...

example 2

[0065]This example demonstrates that storage of skin equivalents for 1 day at 2-8 C is superior to storage at 20-25 C.

Summary:

[0066]STRATAGRAFT® skin tissue is a living skin substitute tissue that has a fully-stratified layer of viable epidermal keratinocytes on a collagen gel containing normal human dermal fibroblasts. The uppermost epidermal layers form a permeability barrier that prevents excessive moisture loss through the epidermis. Assays that measure these key structural and functional properties (viability, histology, and barrier function) have been identified as stability-indicating assays for monitoring the quality of STRATAGRAFT® skin tissue over time.

[0067]The production process for STRATAGRAFT® skin tissue lasts 31 days. At the end of the production process, STRATAGRAFT® skin tissues are removed from organotypic culturing conditions and placed onto HEPES-buffered nutrient-agarose shipping chambers, which are designed to maintain the viability, barrier function, and hist...

example 3

[0074]This example demonstrates that skin equivalents stored for 8 days at 2-8 C are comparable to, or superior to, tissues stored for only 1 day at 20-25 C. Reduction of the storage temperature has been shown to maintain tissue quality comparable to tissues stored at 20°-25° C. (See Example 2). The ability to store STRATAGRAFT® tissue for eight days at 2-8° C. would increase the number of days STRATAGRAFT® tissue is available for clinical use. This study tested the comparability of tissues stored for one day at 20-25° C. with tissues stored at 2-8° C. for eight days. Tissue viability was improved in the tissues that were stored at 2-8° C., even though these tissues were stored for seven additional days.

Experimental Design:

[0075]This study used one batch of tissues manufactured under cGMP at the WCBF and two batches produced at the Stratatech pilot production facility. One tissue from each batch was analyzed on process day 28. The remaining six tissues were fed on day 28 and 30, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Timeaaaaaaaaaa
Permeabilityaaaaaaaaaa
Login to view more

Abstract

The present invention relates generally to systems and methods for storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for producing, transporting, storing and using skin equivalents produced by organotypic culture at reduced temperatures, preferably from 2-8 degrees Celsius. The methods include sterile packaging of the grafts so that the sterility and integrity of the package is maintained until the time of use for grafting purposes.

Description

[0001]This application claims the benefit of U.S. Prov. Appl. 60 / 987,911 filed Nov. 14, 2007, the entire contents of which are incorporated by reference herein.[0002]This invention was made with government support under grant number NIST 70NANB3H3011 awarded by the Advanced Technology Program. The government has certain rights in the invention.FIELD OF THE INVENTION[0003]The present invention relates generally to systems and methods for shipping and storing skin equivalents made by organotypic culture that are to be used for skin grafting to human patients.BACKGROUND[0004]The emerging field of tissue engineering (TE) is poised to make enormous progress in the treatment of organ disease and dysfunction in the coming decade. In 2001, there were 23 cell-based therapeutics approved for market in the United States (U.S.) and Europe, of which nine were skin substitutes or grafts, and 100 more products were in development. (De Bree, Genomics-based Drug Data Report and Regenerative Therapy ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): B65B55/00C12N5/08B65D81/18
CPCA01N1/02A01N1/0273A01N1/0263A01N1/0231
Inventor ALLEN-HOFFMANN, B. LYNNPIRNSTILL, JOHN C.
Owner STRATATECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap